Scarica l'app Stockscreener
0.46
6.08%
-0.0298
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Gt Biopharma Inc Borsa (GTBP) Ultime notizie
GT Biopharma (GTBP) Revenue BreakdownMain Composition - Moomoo
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs - The Globe and Mail
GT BIOPHARMA INC (GTBP) Stock Chart - ChartMill
GT Biopharma (GTBP) plans reverse stock split and larger 2022 incentive plan - Stock Titan
Enterprise value to EBITDA forward of GT Biopharma, Inc. – NASDAQ:GTBP - TradingView
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs - Morningstar
Enterprise value to EBITDA forward of GT Biopharma Inc – MUN:OXIA - TradingView
Enterprise value to revenue forward of GT Biopharma, Inc. – NASDAQ:GTBP - TradingView
Price to book forward of GT Biopharma Inc – FWB:OXIA - TradingView
Enterprise value to EBITDA forward of GT Biopharma Inc – FWB:OXIA - TradingView
Enterprise value to revenue forward of GT Biopharma Inc – FWB:OXIA - TradingView
Enterprise value to EBIT forward of GT Biopharma, Inc. – NASDAQ:GTBP - TradingView
Price to sales forward of GT Biopharma Inc – FWB:OXIA - TradingView
Price to earnings forward of GT Biopharma Inc – FWB:OXIA - TradingView
GT Biopharma Inc Actuals & Estimates (SWB:OXIA) - TradingView
GT Biopharma Inc (GTBP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OXIA Forecast — Price Target — Prediction for 2027 - TradingView
GT Biopharma Inc Actuals & Estimates (NASDAQ:GTBP) - TradingView
GTBP Forecast — Price Target — Prediction for 2027 - TradingView
GT Biopharma Inc (GTBP) Valuation: PE, PB & Fair Value Analysis - TradingKey
GT Biopharma Inc (GTBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GTBP PE Ratio & Valuation, Is GTBP Overvalued - Intellectia AI
GT Biopharma Inc (GTBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GT Biopharma Stocklong-term cancer therapy strategy under review - AD HOC NEWS
GT Biopharma (NASDAQ: GTBP) proposes reverse split and 3.5M share plan increase - Stock Titan
GT Biopharma Inc (GTBP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GT Biopharma Inc (GTBP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GT Biopharma Inc (GTBP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GT Biopharma Inc (GTBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GT Biopharma Inc (GTBP) Institutional Confidence - TradingKey
GTBP Q1 2026 Earnings: EPS Misses Estimates, Stock DeclinesPretax Income Report - Město Břeclav
GT Biopharma, Inc. Announces Amendment to Bylaws in June 2026 SEC Form 8-K Filing - Minichart
GTBP Q1 2026 Earnings: Wider-than-Expected Loss but Stock GainsForward EPS Estimate - newsline.com
GT Biopharma Lowers Stockholder Quorum to One-Third - TipRanks
GT Biopharma (NASDAQ: GTBP) lowers meeting quorum to one-third - Stock Titan
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell - GlobeNewswire
GT Biopharma stock (US36254L1098): FDA green light for new TriKE program puts focus on pipeline - AD HOC NEWS
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet - The Manila Times
GT Biopharma, Inc. - MLQ.ai
GTBP Q1 2026 Earnings: EPS Miss Weighs on Sentiment as Biotech Advances PipelineQuarterly Earnings Report - newsline.com
Precision Oncology Platforms Converge as FDA Accelerates Treatment Innovation - Baystreet.ca
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - The Globe and Mail
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - Benzinga
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives - The Manila Times
GT Biopharma Provides Update on Pipeline Discovery - GlobeNewswire
EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout - Benzinga
GT Biopharma Inc stock (US36254L1098): Nasdaq micro-cap edges lower ahead of valuation focus - AD HOC NEWS
The $13 Million Company Teaching the Immune System to Hunt Cancer - Quantisnow
SEC Says Former GT Biopharma CEO Used Cancer Research Funds to Buy Beverly Hills Mansion - gritdaily.com
GT Biopharma (GTBP) Maintains Support Zone Amid Modest UptickOption Breadth - newsline.com
GT Biopharma Inc. (GTBP) Falls Over 10% as Biotech Sentiment WeakensADD Alert - The Legal Advocate
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):